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Abstract
Hyperglycemia leads to excess production of reactive oxygen species (ROS), lipid peroxidation and protein glycation that may impair
cellular calcium homeostasis and results in calcium sequestration and dysfunction in diabetic tissues. Stobadine (ST) is a pyridoindole
antioxidant has been postulated as a new cardio- and neuroprotectant. This study was undertaken to test the hypothesis that the treatment with
ST inhibits calcium accumulation, reduces lipid peroxidation and protein glycation and can change Ca2 + ,Mg2 + -ATPase activity in diabetic
animals. The effects of vitamin E treatment were also evaluated and compared with the effects of combined treatment with ST. Diabetes was
induced by streptozotocin (STZ, 55 mg/kg i.p.). Some of diabetic rats and their age-matched controls were treated orally with a low dose of
ST (24.7 mg/kg/day), vitamin E (400–500 IU/kg/day) or ST plus vitamin E for 10 weeks. ST and vitamin E separately produced, in a similar
degree, reduction in diabetes-induced hyperglycemia. Each antioxidant alone significantly lowered the levels of plasma lipid peroxidation,
cardiac and hepatic protein glycation in diabetic rats but vitamin E treatment was found to be more effective than ST treatment alone.
Diabetes-induced increase in plasma triacylglycerol levels was not significantly altered by vitamin E treatment but markedly reduced by ST
alone. The treatment with each antioxidant completely prevented calcium accumulation in diabetic heart and liver. Microsomal Ca2 + ,Mg2 + -
ATPase activity significantly decreased in both tissues of untreated diabetic rats. ST alone significantly increased microsomal Ca2 + ,Mg2 + -
ATPase activity in the heart of normal rats. However, neither treatment with ST nor vitamin E alone, nor their combination did change cardiac
Ca2 + ,Mg2 + -ATPase activity in diabetic heart. In normal rats, neither antioxidant had a significant effect on hepatic Ca2 + ,Mg2 + -ATPase
activity. Hepatic Ca2 + ,Mg2 + -ATPase activity of diabetic rats was not changed by single treatment with ST, while vitamin E alone
completely prevented diabetes-induced inhibition in microsomal Ca2 + ,Mg2 + -ATPase activity in liver. Combined treatment with ST and
vitamin E provided more benefits in the reduction of hyperglycemia and lipid peroxidation in diabetic animals. This study describes potential
mechanisms on cellular effects of ST in the presence of diabetes-induced hyperglycemia that may delay or inhibit the development of diabetic
complications. The use of ST together with vitamin E can better control hyperglycemia-induced oxidative stress.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
A number of mechanisms, including hyperglycemia,
glycosylation of proteins and oxidative stress, have been
proposed to contribute to the pathogenesis of cellular
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dysfunction leading to cardiovascular, hepatic and other
complications of diabetes [1,2]. Hyperglycemia has been
shown to generate reactive oxygen species (ROS) such as
superoxide radicals from autooxidation of glucose, and
resultant increase in cellular lipid peroxidation in diabetic
patients and animals [3,4]. Excess production of ROS may
lead to cellular injury through nonspecific modification and
disruption of proteins, phospholipids and nucleic acids [5].
Critical sites of ROS attack are the cell membrane and the
membranes of intracellular organelles. The disruptive effect
of ROS involves membrane lipid peroxidation and mem-
brane protein modification, which may produce alterations
in the membrane structure and function including fluidity,
permeability, enzyme activity, ion channels and transport,
and receptor proteins. Data obtained from animals
and patients with diabetes showed that abnormal intracel-
lular calcium metabolism is widespread in tissues [6], and
intracellular calcium levels are increased in many tissues
including heart [7–10]. Similarly, hepatocyte calcium
sequestration and turnover are also increased in both acute
and chronic experimentally induced diabetes [11,12]. The
activities of membrane ATPases (i.e. Ca2 + ,Mg2 + -ATPase
and Na + ,K + -ATPase) has been shown to be abnormal in
diabetic state. Decreased Ca2 + -ATPase activity has been
reported in diabetic heart [7,8,10]. In contrast, streptozoto-
cin (STZ)-induced diabetes led to an increase in hepatic
plasma membrane Ca2 + -ATPase activity of rats [14]. The
studies imply that the nature of the alterations is tissue-
specific and may depend on the level of blood glucose or
insulin, or both. Membrane Ca2 + ,Mg2 + -ATPase is respon-
sible for the fine-tuning of intracellular calcium and the
Na + –Ca2 + exchanger for rapid ejection of the excess
calcium that has entered the cell [15]. Insufficient
Ca2 + ,Mg2 + -ATPase activity has been suggested as contri-
buting factor in the development of diabetic cardiomyop-
athy [7,8]. The effects of ROS on the enzyme may be very
specific and may include selective alterations of its active
sites resulting in inhibition of its activity [16–19].
Supplementation with antioxidants has been shown to
decrease oxidative stress and complications in animal mod-
els of diabetes [20,21] and in diabetic patients [22]. Diabetes-
induced defects in the homeostasis and the transport of
intracellular calcium has been shown to decrease or recover
by the treatment of diabetic animals with some antioxidant
compounds, such as N-acetyl cysteine, beta-carotene, vita-
min E, trolox C and pyridoxine [19,23,24]. Stobadine (ST),
( )-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexa-hydro-1H-pyr-
ido[4,3-b] indole, was shown to be able to scavenge
hydroxyl, alkoxyl and peroxyl radicals, weakly superoxide,
and to quench singlet oxygen, to repair oxidized amino acids
and to preserve oxidation of SH groups by one-electron
donation [25]. It was demonstrated that in free radical
generating systems in vitro, ST and some other lipophilic
and water-soluble antioxidants, including butylated hydrox-
ytoluene, lipoic acid and vitamin E, are able to decrease the
effects of oxidative stress on tissue Ca2 + -ATPase activity
and calcium accumulation [16,18,24,26]. We recently
showed that the treatment of diabetic rats with a low dose
of ST attenuates tissue markers of oxidative stress and other
diabetes-induced abnormalities in brain [27], heart [28] and
aorta [29]. Since the question of the effect of ST on calcium
homeostasis in diabetes mellitus has not yet been addressed,
the main purpose of the present study was to evaluate the
effects of ST on cardiac and hepatic calcium metabolism in
STZ-diabetic rats. For this purpose, the amount of calcium
and the activity of Ca2 + -ATPase in heart and liver micro-
somes of normal and STZ-diabetic rats, treated or untreated
with ST, were determined. Secondly, we compared the effect
of ST treatment alone with that of vitamin E. Since different
antioxidant compounds may act synergistically and some
combinations may be more effective than any one compound
alone, the effects of ST plus vitamin E treatment were also
evaluated and compared with the effects of treatment with
each agent alone. The effects of ST and vitamin E on plasma
triacylglycerol levels, lipid peroxidation and tissue protein
glycation were also measured to elucidate the underlying
mechanisms.
2. Materials and methods
2.1. Induction of diabetes and treatment protocols
Male Wistar rats, body weight 250–300 g, were fed a
standard rat chow diet and had access to water ad libitum.
Diabetes was induced by a single intraperitoneal injection of
STZ (55 mg/kg body weight) to animals fasted overnight.
Diabetes was verified 48 h later by measuring tail vein
blood glucose, and the rats with blood glucose of 300 mg/dl
or more were considered diabetic. Two days after injection
of STZ or vehicle, rats were divided into the following
groups: (1) untreated diabetic rats (n = 12); (2) diabetic rats
treated with ST (24.7 mg/kg/day, orally) (n = 11); (3) dia-
betic rats treated with vitamin E (alpha-tocopheryl acetate,
400–500 IU/kg/day, orally) (n = 11); (4) diabetic rats treated
with both ST and vitamin E, as given in protocols 2 and 3
(n = 10); (5) untreated control rats (n = 9); (6) control rats
treated with ST as given in protocol 2 (n= 5); (7) control rats
treated with vitamin E, as given in protocol 3 (n = 5); (8)
control rats treated with ST plus vitamin E as given in
protocol 4 (n = 5). The dose regimen of ST or vitamin E was
chosen according to some previous studies [20,25]. The
animals were treated for a period of 10 weeks beginning 48
h after either vehicle or STZ injection. ‘‘The principles of
laboratory animal care’’ (NIH publication no. 85-23, revised
1985) were observed.
2.2. Measurement of blood glucose, triacylglycerol and
thiobarbituric acid reactive substances (TBARS)
Blood glucose and triacylglycerol concentrations were
measured by AccutrendR GCT meter (Roche Diagnostics).
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TBARS, end products of lipid peroxidation, were meas-
ured fluorometrically in plasma [30].
2.3. Membrane-enriched microsome preparation
Heart and liver tissues were weighed and homogenised in
six volumes of freshly prepared buffer A containing: 0.3
mol/l sucrose, 10 mmol/l HEPES–HCl pH 7.4 and 2 mmol/l
dithiothreitol. A Teflon/glass homogeniser (Omni mixer
homogeniser model 18074, Omni Int., CT, USA) was used
for homogenisation of tissues. The homogenates were
centrifuged at 85,000 g for 75 min, the supernatant
discarded and the pellets were resuspended in the original
volume of buffer A containing 0.6 mol/l KCl (using four
strokes) and centrifuged again at 85,000 g for 75 min.
The pellets were then resuspended in the original volume of
buffer A. After centrifugation at 85,000 g for 75 min
(Beckman L 7, Beckman Instruments Inc., Fullerton, CA),
the pellets were suspended in buffer A (using four strokes)
at a protein concentration of 2–7 mg/ml. Samples were kept
frozen at  60 jC until further use. Isolation procedure was
performed at + 4 jC [31].
2.4. Determination of Ca2+-ATPase activity
Ca2 + -ATPase activity was measured spectrophotometri-
cally (Pye Unicam SP8-100 UV spectrophotometer, PYE
Unicam Ltd., Cambridge, England), as described previously
[32]. The incubation medium contained: 120 mmol/l KCl,
60 mmol/l HEPES, pH 7.0 (at 37 jC), 1 mmol/l MgCl2, 0.5
mmol/l K2-ATP, 0.2 mmol/l NADH, 0.5 mmol/l PEPA, 1 IU
pyruvate kinase, 1 IU lactate dehydrogenase/ml and 500
Amol/l EGTA. After preincubation of the assay medium
(total volume of 1 ml) for 4 min at 37 jC, 75-Ag ATPase
was added to the medium. After 2 min, the reaction was
started by addition of 600 Amol/l CaCl2. Determination of
ATPase activity was followed by continuous measurement
of absorbance at 365 nm.
2.5. Determination of tissue calcium levels and protein
glycation
Tissue calcium levels were analysed by atomic absorp-
tion spectrophotometry (Perkin Elmer 2380) according to
the wet-ashing procedure with nitric acid.
Protein glycation in microsomal fractions was measured
as described previously [33].
2.6. Drugs and statistical analysis
All chemicals except ST were purchased from Sigma
Chemical (St. Louis, MO, USA). ST dipalmitate was
obtained from the Slovak Academy of Sciences. Data are
expressed as meanF S.E. They were first subjected to
Bartlett’s test for homogeneity of variances and were given
a log transformation if necessary. One-way analysis of
variance was then performed, followed by the Student–
Neuman–Keuls test to estimate the significance of differ-
ences for individual between-group comparisons. For the
statistical evaluation of starting and final blood glucose
concentrations within groups, Student’s t test was used.
3. Results
The final blood glucose concentrations of untreated
diabetic rats were about four times higher than in normal
control rats (Fig. 1). A treatment with each agent alone
produced a significant fall in blood glucose levels of
diabetic animals. The magnitude of the blood glucose low-
ering effect of ST treatment was found to be comparable to
the effects of vitamin E treatment. Combination of ST and
vitamin E provided some further benefit on blood glucose
control; nevertheless, at the end of the treatments, diabetic
rats were still hyperglycaemic when compared with normal
control rats (Fig. 1).
Plasma triacylglycerol concentrations significantly
increased in untreated diabetic rats (Fig. 2). Single treatment
with ST resulted in a marked decrease in plasma triacylgly-
Fig. 1. Blood glucose levels of control (C) and diabetic (D) animals untreated
or treated with stobadine (ST), vitamin E (E) or stobadine plus vitamin E
(ST+E). Data are reported as meansF S.E. The blood glucose concen-
trations of all diabetic animals were significantly different from the control
animals untreated or treated with antioxidants. Start: 2 days later of STZ
injection. Final: at the end of the treatment period. *P < 0.05, **P< 0.01 vs.
starting within group.
Fig. 2. Plasma triacylglycerol levels of control (C) and diabetic (D) animals
untreated or treated with stobadine (ST), vitamin E (E) or stobadine plus
vitamin E (ST+E). Data are reported as meansF S.E. #P < 0.05, yP < 0.01,
fP< 0.001 vs. untreated-control (C) animals. **P < 0.01, ***P < 0.001 vs.
untreated-diabetic (D) animals.
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cerols while vitamin E alone was unable to induce a signifi-
cant reduction in elevated triacylglycerols of diabetic rats
(Fig. 2). Combined treatment has no further effect on the
decreasing of triacylglycerol levels of diabetic animals.
The levels of TBARS, end products of lipid peroxidation,
were markedly elevated in plasma of diabetic rats compared
to those in controls (Fig. 3). This increase was partially
prevented by treatment with either ST or vitamin E alone.
In the prevention of plasma lipid peroxidation, the combined
therapywas significantly more effective than treatment with a
single agent, and it provided almost normalised plasma
TBARS in diabetic animals (Fig. 3).
In normal control rats, treatment with each antioxidant
studied, as well as their combination, led to a significant
reduction of cardiac protein glycation. In these animals,
hepatic protein glycation was also inhibited by ST alone, yet
not by vitamin E. Glycation of proteins significantly
increased in heart and liver of untreated diabetic rats (Fig.
4). In heart of diabetic rats, an increase in protein glycation
was significantly but not completely prevented by vitamin E
treatment; while this vitamin completely prevented diabetes-
induced changes in glycation of hepatic proteins. ST, when
given alone, was also effective in the prevention of protein
glycation increase in both diabetic heart and liver; however,
in comparison with vitamin E, the inhibitory effect of ST
was moderate. When compared with the effect of viatamin E
treatment alone, the combination of the two antioxidants did
not provide an additional benefit on either cardiac or hepatic
protein glycation of diabetic rats (Fig. 4).
Total calcium levels were markedly increased in heart and
liver of untreated diabetic rats (Fig. 5). In the heart, treatment
with either ST or vitamin E resulted in a significant decrease
in calcium levels in both nondiabetic control and diabetic rats.
In the treatment with vitamin E alone or two agents together,
the calcium levels of the diabetic heart were found to be lower
than those of normal control animals. In the liver, neither ST
nor vitamin E treatment did significantly change calcium
levels of normal control rats, but in diabetic rats calcium
overload was completely prevented (Fig. 5).
Microsomal Ca2 + -ATPase activity significantly de-
creased in heart and liver of untreated diabetic rats (Fig. 6).
The inhibitory effect of diabetes on Ca2 + -ATPase activity
was observed to be higher in heart than that in liver. ST alone
or its combination with vitamin E significantly increased
microsomal Ca2 + -ATPase activity in the heart of normal
rats. However, neither treatment with ST nor vitamin E
alone, nor their combination did change cardiac Ca2 + -
ATPase activity in diabetic heart. In normal rats, neither
antioxidant had a significant effect on hepatic Ca2 + -ATPase
activity. Hepatic Ca2 + -ATPase activity of diabetic rats was
Fig. 3. Effects of stobadine (ST) and vitamin E (E) treatments on plasma
lipid peroxidation levels (Thiobarbituric acid reactive substances (TBARS)
of the animals. Data are reported as meansF S.E. #P < 0.05, yP < 0.01,
fP< 0.001 vs. untreated-control (C) animals. **P < 0.01, ***P < 0.001 vs.
untreated-diabetic (D) animals.
Fig. 4. Effects of stobadine (ST) and vitamin E (E) treatments on the
glycation of proteins in liver and heart of the animals. Data are reported as
meansF S.E. #P< 0.05, yP < 0.01, CP< 0.001 vs. untreated-control (C)
animals. *P< 0.05, **P < 0.01, ***P< 0.001 vs. untreated-diabetic (D)
animals.
Fig. 5. Tissue calcium concentrations in control (C) and diabetic (D) animals
untreated or treated with stobadine (ST), vitamin E (E) or stobadine plus
vitamin E (ST +E). Data are reported as meansF S.E. #P < 0.05, yP < 0.01,
CP < 0.001 vs. untreated-control (C) animals. *P < 0.05, **P < 0.01,
***P< 0.001 vs. untreated-diabetic (D) animals.
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not changed by the treatment with single ST, while vitamin E
alone completely prevented diabetes-induced inhibition in
microsomal Ca2 + -ATPase activity in liver (Fig. 6).
4. Discussion
Abundant information is now available on changes in
plasma membrane and subcellular organelles, which are
responsible for the impaired intracellular calcium homeo-
stasis in diabetic cardiomyopathy and other complications of
diabetes mellitus [6,7,9,10]. Some of these include abnor-
malities in the following variables: calcium binding, influx of
calcium through the L-type calcium channels, Na + ,K + -
ATPase activity, Na + –Ca2 + exchange, H + –Na + exchange
and Ca2 + ,Mg2 + -ATPase activity etc. The Ca2 + -ATPase is
the major active calcium transport protein responsible for the
maintenance of normal intracellular calcium levels in a
variety of cell types. Maintenance of the cation gradient by
Ca2 + -ATPase is of fundamental importance in the control of
hydration, volume, nutrient uptake and fluidity of cells, and is
also essential for the contractility and excitability properties
of muscles [6,7]. In the present study, microsomal
Ca2 + ,Mg2 + -ATPase activity was depressed by STZ-diabetes
in heart and liver of rats. This event was accompanied to
increased total calcium levels. Our findings are in agreement
with previous observations showing that the membrane
abnormalities in Na + ,K + -ATPase, Na + –Ca2 + exchange
and Ca2 + -pump activities led to the occurrence of intra-
cellular calcium overload in experimental rat models of
diabetes [7,10,13,34]. Depressed myofibrillar and sarcolem-
mal Ca2 + -ATPase activity and sarcoplasmic reticulum cal-
cium uptake were reported as important mechanisms
responsible for the cardiac dysfunction and cardiomyopathy
exhibited by insulin-deficient (Type I) diabetic animals
[7,10,13,34].
The increased intracellular concentration of calcium may
be explained by the osmotic activity of high glucose (cell
shrinkage), demonstrated to activate G protein(s), most likely
through a stretch receptor, which in turn stimulates calcium
channels inhibitable by verapamil, nifedipine and amlodi-
pine, thus permitting a calcium influx into cardiac myocytes
[9]. The increased cardiac affinity for calcium in diabetic rats
was also reported to be due to changes in sarcolemmal lipid
bilayer composition secondary to diabetes-induced hyper-
lipidaemia [35]. Diabetes-induced hyperlipidemia and the
alterations in membrane phospholipids and fatty acids have
been shown to depress membrane-bound enzyme activities,
which influence intracellular calciummetabolism resulting in
cardiac dysfunction [34]. As indicated before, plasma mem-
brane and the membranes of intracellular organelles are
crucial targets of ROS attack. Oxidative insult was found to
lead to a decrease in Ca2 + -ATPase activity in heart [36,37] or
brain microsomes [18]. Decreased membrane fluidity
induced by increased oxidative stress has been linked with
the aforementioned abnormalities in calcium metabolism
[18]. The present study provided once again evidence that
there are significant increase in plasma triacylglycerol levels
and the peroxidation of lipids in diabetic animals. As it is well
known, hyperglycemia results in increased oxidative stress
from excessive ROS production from the auto-oxidation of
glucose and glycated proteins [2,5,38]. The increased ROS
activity initiates peroxidation of lipids and MDA accumu-
lation, which in turn can stimulate glycation of proteins in
diabetes [4,38]. Another possibility involves the modification
of enzyme molecules either by direct oxidation or by mod-
ification mediated by products of lipid peroxidation [39]. A
decrease in ATPase enzyme activity in any diabetic tissue
could be due to excessive nonenzymatic glycation of the
enzyme itself and/or of calmodulin [40]. Ca2 + -ATPase was
shown to be particularly sensitive to cross-linking and the
concomitant decrease in protein rotational mobility due to
protein aggregation [36]. In the present study, cardiac and
hepatic protein glycation was markedly increased in STZ-
diabetic rats; in the light of previous observations, both
glycosylation of enzyme proteins and/or inhibition of its
activity by lipid peroxidation products seem to be major
contributing factors associated with abnormal calcium
homeostasis in diabetic animals.
In the present study, we demonstrated for the first time
that 10 weeks of ST treatment completely prevented cardiac
and hepatic calcium accumulation without a significant
amelioration in Ca2 + -ATPase activity in STZ-diabetic rats.
The magnitude of this effect of ST was parallel with the
same effect of vitamin E in both tissues; a combination of
ST plus vitamin E did not produce a further effect on total
Fig. 6. Microsomal Ca2 + -ATPase activity in control (C) and diabetic (D)
animals untreated- or treated with stobadine (ST), vitamin E (E) or stobadine
plus vitamin E (ST+E). Data are reported as meansF S.E. #P< 0.05,
yP < 0.01, CP < 0.001 vs. untreated-control (C) animals. * P < 0.05,
**P < 0.01, ***P< 0.001 vs. untreated-diabetic (D) animals.
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calcium amount in diabetic tissues. On the other hand, the
effect of each antioxidant on microsomal Ca2 + -ATPase
activity was tissue-specific. In heart of normal control rats,
ST treatment alone led to an increase in Ca2 + -ATPase
activity, but did not produce a significant change in
depressed Ca2 + -ATPase activity in diabetic rats. In liver,
however, ST treatment alone had no significant effect on
Ca2 + -ATPase activity in either control or diabetic animals.
In diabetic animals, vitamin E, although unable to prevent
Ca2 + -ATPase depression in heart, completely protected
hepatic Ca2 + -ATPase activity from the destructive effect
of STZ-diabetes. In addition, neither ST nor vitamin E did
alter hepatic Ca2 + -ATPase activity in normal animals.
Previous studies have reported that supplementation with
some antioxidants prevents lipid peroxidation, hemoglobin
glycosylation and inhibition of Na + ,K + -ATPase and/or
Ca2 + -ATPase activity caused by hyperglycemia in various
cells [19,23,24]. The exact mechanism(s) of the effects of
the both antioxidants on abnormal intracellular calcium
regulation of diabetic heart and liver are not fully known.
As demonstrated previously, ST prevents the decrease in
membrane fluidity and nonspecifically inhibits various
excitable channels, and diminishes in a concentration-
dependent manner calcium (L-type) inward currents [25]
that may account for its preventive effect on calcium
accumulation in diabetic tissues. In endoplasmic reticulum
membranes of synaptosomes and erythrocytes, ST has been
shown to attenuate calcium permeability already increased
by a free radical generating system in vitro [16,18]. In this in
vitro system, brain Ca2 + -ATPase activity was protected by
ST, and the efficiency of ST to prevent calcium transport
changes was demonstrated to depend on the presence of
glutathione and was similar to that of a good chain-breaking
antioxidant, butylated hydroxytoluene [18]. In the afore-
mentioned study, in contrast to ST, vitamin E was shown to
be less potent to confer the defence against ROS-induced
changes in calcium regulation [18]. It has been suggested
that inhibition of Ca2 + -ATPase is not based on direct
protein modifications, but is rather mediated by changes
in membrane fluidity and protein–lipid interaction [18]. In
the present study, we observed that in vivo treatment with a
low dose of ST partially prevented glycation of cardiac and
liver proteins and the peroxidation of plasma lipids. These
effects of ST treatment alone were less potent than the
corresponding effects of vitamin E treatment in diabetic
animals. It has been shown that ST inhibits protein glycation
and lipid peroxidation [25,41,42]. The inhibitory effect of
ST on hyperglycemia-induced lipid peroxidation could be a
result of the scavenging of ROS. STwas shown to be able to
scavenge hydroxyl, alkoxyl and peroxyl radicals, weakly
superoxide, and to quench singlet oxygen, to repair oxidized
amino acids and to preserve oxidation of SH groups by one-
electron donation [25]. The protein glycation-inhibiting
effect of ST has been demonstrated in an experimental in
vitro glycation model [42]. Since ST did not affect the
covalent binding of glucose, the protective effect of ST has
been attributed to its ability to eliminate free radical inter-
mediates of glyco-oxidation reactions, operative after the
preceding glycation step [42,43]. ST inhibits glucose-
induced chromo- and fluorophore formation, interferes with
metal-catalysed oxidation reaction following after the gly-
cation step and limits the damage from glycation-induced
processes [43]. Blood-glucose-lowering effect of ST treat-
ment, started 2 days later of STZ injection, might be directly
related to its free radical (peroxyl radicals) scavenging
properties, which may protect pancreatic beta cells against
the STZ toxicity [25].
Vitamin E treatment alone completely prevented protein
glycation in diabetic liver, which was parallel with the
protection of microsomal Ca2 + -ATPase. This implies that
impaired Ca2 + -ATPase is more likely a consequence of
increased protein glycation in diabetic tissue. This phenom-
enon, however, may be valid for diabetic liver only. In the
heart of diabetic animals, the findings suggest that other
factors are also involved in the regulation of calcium homeo-
stasis affected by ST and vitamin E. These factors seem
unlikely to be directly linked with lipid peroxidation since
both antioxidants significantly prevented overproduction of
lipid hydroperoxides both in plasma (as observed in this
study) and in heart [28] of diabetic animals. In earlier studies,
other investigators found that administration of vitamin E in
a combination with other antioxidants, N-acetyl cysteine,
beta-carotene and vitamin C, prevented both diabetes- and
galactosemia-induced elevations in oxidative stress, and
protected myocardial and retinal Na + ,K + -ATPase and
Ca2 + -ATPases against oxidative damage [19,44]. Another
report stated that pre-treatment of animals with vitamin E
attenuated depression in sarcoplasmic reticulum calcium
transport, intracellular calcium accumulation and heart dys-
function in catecholamine-induced cardiomyopathy [26].
Vitamin E can block the glycation of proteins by inhibiting
MDA formation [38]. However, some reports suggest that
the Ca2 + -releasing and/or -retaining effects of alpha-toco-
pherol may be independent of pro- and/or antioxidant
activities [45].
Our study provided the first evidence that a low dose of
ST is able to lower blood glucose and triacylglycerol levels
and to prevent lipid peroxidation, protein glycation and
tissue calcium accumulation in STZ-diabetic rats. The
inhibitory effect of ST on calcium overload seems to be
dependent largely on its aforementioned beneficial effects
but is unlikely to be directly linked with the membrane
Ca2 + -ATPase activity since ST treatment is unable to
prevent Ca2 + -ATPase reduction in diabetic heart and liver.
The increasing effect of ST on cardiac Ca2 + -ATPase activ-
ity in normal control rats may be attributed to its lowering
effect on calcium amount in this tissue. On comparing the
two compounds, vitamin E was found to be more effective
than ST in the prevention of lipid peroxidation and protein
glycation. These antioxidants provide more benefits only in
the prevention of diabetes-induced hyperglycemia and lipid
peroxidation when used in combination for the treatment of
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diabetes. In addition, ST is a potent inhibitor of plasma
triacylglycerol levels. This study describes potential mech-
anisms on cellular effects of ST in the presence of hyper-
glycemia that may delay or inhibit the development of
diabetic complications. The use of both antioxidants
together can provide a better control on hyperglycemia-
induced oxidative stress.
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